Original Article

Silencing of HIF-1α inhibited the expression of IncRNA NEAT1 to suppress development of hepatocellular carcinoma under hypoxia

Xiuming Zhang1*, Zheng Kang1*, Xiaodong Xie1, Wei Qiao1, Lei Zhang1, Zhen Gong2, Yan Chen1, Wenrong Shen1

1Department of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China; 2Department of Gynecology, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China. *Equal contributors.

Received December 30, 2019; Accepted June 2, 2020; Epub July 15, 2020; Published July 30, 2020

Abstract: Background: We aimed to explore the relationship between hypoxia-inducible factors-1α (HIF-1α) and IncRNA nuclear-enriched abundant transcript 1 (NEAT1), and their functions on hepatocellular carcinoma (HCC) under hypoxia. Methods: HIF-1α and NEAT1 levels in HCC tissues and corresponding non-tumor tissues were determined by qRT-PCR, and the correlations of their levels in HCC tissues were analyzed by Pearson test. The relationship between overall survival and the two genes (HIF-1α and NEAT1) for HCC patients was detected by log-rank test. Clinico-pathological features of NEAT1 in HCC patients were collected. HIF-1α and NEAT1 levels in HCC cells were measured by qRT-PCR and Western blot, and their relationship was determined by co-immunoprecipitation (Co-IP) assay. Cell viability, migration and invasion were detected by CCK-8, scratch wound healing and transwell assay, respectively. The interaction of NEAT1 with HIF-1α in tumor development was determined by xenograft tumor assays in nude mice. Results: NEAT1 and HIF-1α were highly expressed and showed a positive relationship in HCC tissues, and specifically, higher NEAT1 expression was positively associated with advanced TNM stage and metastasis in HCC patients. Up-regulated NEAT1 or HIF-1α in HCC patients had poorer prognosis. NEAT1 was induced by HIF-1α and suppressed by siHIF-1α. NEAT1 overexpression further promoted development of HCC under hypoxia while promoting cell viability, migration and invasion and suppressing apoptosis, and such effects were reversed by down-regulating HIF-1α. NEAT1 overexpression promoted tumor growth, which was reversed by down-regulating HIF-1α. Conclusion: HIF-1α knockdown inhibits NEAT1 expression, which suppresses progression of HCC and improves its prognosis.

Keywords: HIF-1α, NEAT1, hepatocellular carcinoma, hypoxia, prognosis

Introduction

Hepatocellular carcinoma (HCC), which accounts for approximately 90% of primary liver cancers, is the main type of primary liver cancer and causes 700,000 deaths annually worldwide [1, 2]. Meanwhile, HCC is also a major cause of cancer-related deaths in China [3]. Though some therapeutic options, such as systemic chemotherapy, targeted therapy, surgical resection, and liver transplant, have been adopted for the management of HCC [4], HCC has a high tolerance to the majority of anticancer treatments, and therefore the 5-year survival rate of HCC patients is still low [5]. Although efforts have been devoted to understanding basic cellular events in HCC, the exact mechanisms of liver carcinogenesis still remain unclear [6]. Thus, it is highly necessary to discover effective prognostic markers and potential molecular mechanism involved in HCC carcinogenesis so as to develop new targeted therapeutic methods for improving the prognosis of HCC patients.

Hypoxia, which can be commonly found in general solid tumors, is often involved in poor prognosis. It promotes cancer cell invasion and metastasis by activating related gene expressions via hypoxia-inducible factors (HIFs) [7]. Hypoxia-inducible factor 1 (HIF1), a heterodimeric transcription factor composed of an α subunit (HIF-1α) and a β subunit (HIF-1β), participates in hypoxic signaling pathways, and HIF-
1α is found to be the most mature factor in studying the relationship between HIF-1 and tumor [8]. HIF-1α controls cellular and systemic homeostatic responses to oxygen availability [9]. Under hypoxia, it recognizes and binds to hypoxia response elements (HREs), activating the transcription of numerous genes to modulate pro-oncogenic events [10, 11]. Pathogenesis of HCC is involved in tumor hypoxia and the activation of HIF [12]. In HCC, HIF-1α exerts a tumorigenic effect by promoting cell migration and invasion [13].

In recent years, multiple long non-coding RNAs (lncRNAs) have been reported to serve as important regulators in different cancers [14, 15], and to be associated with the promotion or inhibition of typical cancer hallmarks, including continuous proliferation, surpassing apoptosis, drug resistance, invasion, and metastasis [16]. Structures and functions of lncRNA nuclear-enriched abundant transcript 1 (NEAT1) have been investigated widely for its significant role in numerous cancer-related pathological changes and metastasis [17]. However, the role of NEAT1 in HCC under hypoxia remains unclear.

The current study explored the expressions of HIF-1α and NEAT1, their correlations in HCC tissues and their relationships with prognosis for HCC patients. We also investigated the relationship between HIF-1α and NEAT1 and their roles in HCC progression in vitro under hypoxia and normoxia, and in tumor progression in vitro.

Materials and methods

Ethics statement

All patients signed the written informed consent before surgery, and Research Ethics Committee of Jiangsu Cancer Hospital (JCH2018-0504298) approved the current study according to the Declaration of Helsinki. In this study, all the animals were used in accordance with the Guidelines of the China Council on Animal Care and Use, and the experiments were approved by the Committee of Experimental Animals of Jiangsu Cancer Hospital (JCH20-19060326). Efforts have been made to minimize pain or discomfort caused to the animals. The animal experiments were performed in Jiangsu Cancer Hospital.

Clinical specimens

Ninety-eight patients who were diagnosed as hepatocellular carcinoma (HCC) and received routine hepatic resection in Jiangsu Cancer Hospital from 02/16/2018 to 03/16/2019 were included in this study. The patients had no radiotherapy or chemotherapy history and were treated by surgery, and fresh tumor samples were obtained from their resected specimens. The clinicopathological characteristics (gender, age, tumor size, HBsAg, liver cirrhosis, histological differentiation, TNM stage, and metastasis) are displayed in Table 1. Tumors and adjacent fresh non-tumor tissues were frozen immediately in liquid nitrogen and stored at -80°C after the resection.

Prognosis analysis

Survival of HCC patients in relation to HIF-1α was analyzed by Kaplan-Meier and log-rank test based on data from The Cancer Genome Atlas (TCGA). Overall survival of NEAT1 in HCC patients was analyzed by Kaplan-Meier and log-rank test based on data from follow-up time (60 months).

Cell hypoxia culture

Two human liver cancer cell lines (Hep3B and SK-Hep1) were purchased from American Type Culture Collection and cultured in DMEM (12100, Solarbio, China) containing 10% fetal bovine serum (FBS; 11011-8611, Solarbio). For hypoxia treatment, the cells were cultured in an in vivo Hypoxia Work Station (Ruskinn Technology Ltd.) under normoxia (21% oxygen) or hypoxia (gas mixture of 1% oxygen, 5% CO₂, and 94% N₂).

Cell transfection

To construct plasmids that express NEAT1, the full-length human NEAT1 sequence was synthesized by RiboBio and subcloned into the pcDNA3.1 vector (V79020, ThermoFisher, USA). For HIF-1α knockdown, 100 pmol of HIF-1α siRNA (siHIF-1α) (siRNA; GenePharma, Shanghai, China) and siRNA negative control (NC) were respectively transfected into the cells. The empty vector was considered as a control (pc-Control) of pcDNA-NEAT1. NC served as a control of siHIF-1α. After seeded into 6-well plates, the cells were cultured for 24 h,
The role of HIF-1α and NEAT1 in hepatocellular carcinoma

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNAs were isolated from the collected tissues and cells by Trizol reagent (15596018, Invitrogen). PrimeScript™ RT Master Mix was used for RT-PCR (RR036B, Takara). Quantitative PCR was performed in 7300 real-time PCR system (Applied Biosystems, USA) using TB Green® Premix Ex Taq™ II (RR820Q, Takara). The conditions were set as follows: incubation at 95°C for 30 min, followed by amplification at 95°C for 5 sec and at 60°C for 34 sec for 40 cycles. Expressions of genes were normalized to that of GAPDH (Sangon Biotech) using 2-ΔΔCT method [18]. The sequences of primers used are displayed in Table 2.

Western blot

Total proteins were extracted from the cells using RIPA buffer (R0010, Solarbio). The supernatant from the total proteins was collected and the concentration was determined by BCA protein assay kit (PC0020, Solarbio). The supernatant (30 μg/lane) was loaded for SDS gel and transferred onto PVDF membranes (FFP32, Beyotime, China) by using an electroblotting apparatus. Non-specific bindings were blocked by incubating the membranes in 5% (w/v) skimmed milk in Tris-buffered saline containing 0.1% Tween-20. The membranes were probed by specific primary antibodies [anti-HIF-1α (Rabbit, 1:1000, ab51608, Abcam, USA) and anti-GAPDH antibody (Mouse, 1:500, ab8245, Abcam, USA)] at 4°C overnight, and washed by TBS containing 0.1% Tween-20. The membranes were then incubated with HRP-conjugated secondary antibodies (Goat Anti-Mouse, 1:1000, ab20519, Abcam, USA; Goat Anti-Rabbit, 1:1000, ab205178, Abcam, USA) at 1:1000 dilution at 37°C for 1 h. After washing the membranes 3 times at an interval of 10 min, the signals were

Table 1. The relationship between NEAT1 and clinical characteristics of HCC patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N</th>
<th>Low NEAT1 expression (n=45)</th>
<th>High NEAT1 expression (n=53)</th>
<th>χ²</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>80</td>
<td>37</td>
<td>43</td>
<td>0.019</td>
<td>0.890</td>
</tr>
<tr>
<td>Female</td>
<td>18</td>
<td>8</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 55</td>
<td>55</td>
<td>26</td>
<td>29</td>
<td>0.093</td>
<td>0.761</td>
</tr>
<tr>
<td>≥ 55</td>
<td>43</td>
<td>19</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 5</td>
<td>56</td>
<td>27</td>
<td>29</td>
<td>0.277</td>
<td>0.598</td>
</tr>
<tr>
<td>≥ 5</td>
<td>42</td>
<td>18</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>0.075</td>
<td>0.785</td>
</tr>
<tr>
<td>Positive</td>
<td>88</td>
<td>40</td>
<td>48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absence</td>
<td>22</td>
<td>10</td>
<td>12</td>
<td>0.002</td>
<td>0.960</td>
</tr>
<tr>
<td>Presence</td>
<td>76</td>
<td>35</td>
<td>41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histological differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>21</td>
<td>10</td>
<td>11</td>
<td>0.033</td>
<td>0.984</td>
</tr>
<tr>
<td>Moderate</td>
<td>35</td>
<td>16</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>42</td>
<td>19</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I + II</td>
<td>46</td>
<td>27</td>
<td>19</td>
<td>5.699</td>
<td>0.017</td>
</tr>
<tr>
<td>III + IV</td>
<td>52</td>
<td>18</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>58</td>
<td>31</td>
<td>17</td>
<td>7.642</td>
<td>0.006</td>
</tr>
<tr>
<td>Yes</td>
<td>40</td>
<td>14</td>
<td>26</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Primer sequences used for quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer sequences (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIF-1α</td>
<td>Forward GAACGTGCAAAAGAAAAGTCTCG</td>
</tr>
<tr>
<td></td>
<td>Reverse CTTATCAAGATGCAGAxCACCA</td>
</tr>
<tr>
<td>NEAT1</td>
<td>Forward CAGTTAGTTTATCGTTCTCCCATCA</td>
</tr>
<tr>
<td></td>
<td>Reverse GTTGTTGTCGTCACCTTTCAACTCT</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward GCTTCGGCAGCACATATAACTAAAT</td>
</tr>
<tr>
<td></td>
<td>Reverse CGCTTCAGAATTTGCCTGTCCAT</td>
</tr>
</tbody>
</table>
The role of HIF-1α and NEAT1 in hepatocellular carcinoma

visualized by ECL detection kit (ECL, Premega, USA) and normalized to GAPDH.

Co-immunoprecipitation (Co-IP) assay
Co-IP assay was performed as described previously [19]. Briefly, the total proteins were extracted from the cell lines and the concentration was determined. The total proteins were incubated with anti-HIF-1α (ab51608, Abcam), or with control IgG antibodies and protein-G agarose beads (Beyotime) overnight at 4°C. The immunoprecipitates were boiled and then analyzed by Western blot.

Cell counting kit-8 (CCK-8) assay
Transfected cells (5×10⁵ per well) were seeded in 96-well plates and cultured for 24 h. Then, CCK-8 solution (10 μL/well, CK04, Japan) was added into the plates for further incubation for 2 h. The absorbance was measured at 450 nm using a microplate reader (SpectraMax iD5, Molecular Devices, US).

Scratch wound healing assay
The cells were cultured in 6-well plates to reach 80-90% confluence, scratched by a 10 μl tip and further cultured for 24 h. The migration rate was calculated from photomicrographs under a 100× inverted microscope (Ts2r-FL, Nikon, Japan).

Invasion assays
The cells were cultured in Transwell chambers (8 mm pores, Corning Inc., Corning, USA) composed of Transwell®-precoated Matrigel™ membrane filter inserts. The 10% FBS was added into the lower chamber and served as the chemoattractant. After 24 h, the remaining cells were gently removed by cotton swabs, while those adhered to lower surface were fixed by 4% methanol for 30 min and stained by 0.1% crystal violet solution for 20 min at 37°C and photographed.

Flow cytometry assay
Cell apoptosis after treatment was determined by flow cytometry using an Annexin V-FITC Apoptosis Detection Kit (CA1020, Solarbio, China). Briefly, the cells were treated and cultured in 6-well plates. After washed by cold sterile PBS, the cells were counted, resuspend-
ed in 1X binding buffer, and incubated with 5 μL of Annexin V-FITC and blended gently for 10 min, followed by incubation with 5 μL of propidium iodide (PI) for 5 min in the dark. Then the cells were diluted with PBS to 500 μL. After that, the apoptotic rate was evaluated by flow cytometry in flow cytometer Accuri™ C6 (BD Biosciences) and the data were analyzed by Cell Quest software 3.3 (Becton-Dickinson).

Animal experiments in vivo
For tumorigenicity in vivo, 20 male BALB/c athymic nude mice (aged 6 weeks old) were randomly divided into four groups, with five mice in each group. SiHIF-1α, pc-NEAT1-transfected or SiHIF-1α, and pc-NEAT1 co-transfected Hep3B cells (1×10⁷ cells in 100 μL) were injected subcutaneously into the left flanks of the nude mice. In the control group, tumor growth was measured every week and when the diameter reached 1 cm, the mice were sacrificed and tumors were weighted. The tumor volume was calculated according to the following equation: 

\[
V = 0.5 \times D \times d^2
\]

\(V = \) volume; \(D = \) longitudinal diameter and \(d = \) latitudinal diameter. The tissue samples were paraffin-embedded and sectioned, and the expressions of HIF-1α protein and NEAT1 were determined by immunohistochemistry and qRT-PCR.

Immunohistochemistry
Immunohistochemistry was performed as previously described [6]. The tissues were sectioned into 4 μm thick, treated with antigen retrieval by heating ethylene diamine tetra acetic acid buffer in a microwave oven. Endogenous peroxidase activity was blocked by incubating the sections in 3% H₂O₂ for 30 min and then rinsed in PBS three times at an interval of 3 min. The sections were incubated with mouse monoclonal antibody against HIF-1α (ab1, 1:500, Abcam) at 4°C overnight and then incubated with secondary antibody (Goat Anti-Mouse, 1:2000, Abcam). The DAB Horseradish Peroxidase Color Development Kit (P0203, Beyotime) was used to develop color for targeting proteins. Next, the sections were redyed by Hematoxylin Staining Solution (C0107, Beyotime).

Statistical analysis
The data were shown as mean ± standard deviation (S.D.). Chi-square test was used to deter-
mine the correlation between NEAT1 and clinical features in liver cancer patients. Paired t-test was performed for paired samples. Correlation coefficients (r) were analyzed by Pearson correlation. Kaplan-Meier plots were analyzed by log-rank test. Comparisons among multiple groups were conducted by one-way ANOVA followed by Bonferroni-t post hoc test. Statistical analyses were performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA), and P < 0.05 was considered to be of statistical significance.

Results

**NEAT1 and HIF-1α were differentially overexpressed in HCC tissues and their overexpressions were associated with poorer prognosis**

QRT-PCR results showed that NEAT1 and HIF-1α were obviously increased in HCC tissues compared with those in adjacent normal tissues (Figure 1A and 1B, P < 0.001). Pearson correlation analysis revealed that HIF-1α expression was positively correlated with NEAT1 expression in HCC specimens (Figure 1C, P < 0.05).

Data on differential expression of HIF-1α in HCC cancer were collected from TCGA. The proportion of surviving HCC patients in the HIF-1α high group (n=184) was significantly lower than that in the HIF-1α low group (n=185), suggesting that HCC patients with low HIF-1α expression could have a better prognosis (Figure 1D, P=0.0026).

As shown in Table 1, HCC patients were divided into two groups, namely, low NEAT1-expression group (n=45) and high NEAT1-expression group (n=53), according to the cut-off value, which was defined as the median value of the NEAT1 level. Clinicopathological analysis showed that there were no statistically significant differences in gender, age, tumor size, HBsAg, and histological differentiation liver cirrhosis between
The role of HIF-1α and NEAT1 in hepatocellular carcinoma

the low NEAT1 and high NEAT1 groups (Table 1, P > 0.05); However, a high level of NEAT1 was found to be significantly associated with advanced tumor-node-metastasis (TNM) stage (Table 1, P=0.017) and metastasis of HCC (Table 1, P=0.006).

Kaplan-Meier plots showed that HCC patients in the high NEAT1-expression group (n=53) had lower overall survival rate (15%-25%) compared with the low NEAT1-expression group (n=45) (Figure 1E, P=0.018).

HIF-1α silencing reduced NEAT1 level in Hep3B and SK-Hep1 cells under hypoxia

SiHIF-1α significantly reduced the protein and mRNA levels of HIF-1α in Hep3B and SK-Hep1 cells (Figure 2A-F, P < 0.05 or P < 0.01 or P < 0.001). Nevertheless, the protein and mRNA
levels of HIF-1α were highly expressed in Hep3B and SK-Hep1 cells under hypoxia (Figure 2A-F, \( P < 0.001 \)), which, however, could be partially reversed by silencing HIF-1α (Figure 2A-F, \( P < 0.001 \)).

Under hypoxia, NEAT1 was highly expressed in Hep3B (Figure 2G, \( P < 0.001 \)) and SK-Hep1 cells (Figure 2H, \( P < 0.001 \)), while this effect was partially reversed by HIF-1α silencing (Figure 2G and 2H, \( P < 0.001 \)). In addition, we found that HIF-1α bound to hypoxia response elements (HRE) in gene promoters of NEAT1 in hypoxic Hep3B and SK-Hep1 cells (Figure 2I), suggesting that HIF-1α can regulate protein-coding genes of NEAT1.

**HIF-1α silencing suppressed the development of HCC by negatively regulating NEAT1 level in Hep3B and SK-Hep1 cells under hypoxia**

Hep3B and SK-Hep1 cells in the hypoxia, pc-control, pc-NEAT1, pc-NEAT1 + siHIF-1α, siHIF-1α groups were exposed to hypoxia, and we observed that hypoxia or NEAT1 overexpression significantly increased the level of NEAT1 in Hep3B (Figure 3A, \( P < 0.001 \)) and SK-Hep1 cells (Figure 3B, \( P < 0.001 \)), while HIF-1α silencing greatly reduced the protein level of NEAT1 (Figure 3A and 3B, \( P < 0.001 \)).

NEAT1 overexpression further promoted the viability of Hep3B (Figure 3C, \( P < 0.001 \)) and SK-Hep1 cells (Figure 3D, \( P < 0.01 \)) under hypoxia. However, HIF-1α silencing significantly suppressed the cell viability under hypoxia (Figure 3C and 3D, \( P < 0.01 \)), which was partially reversed NEAT1 overexpression (Figure 3C and 3D, \( P < 0.001 \)). Moreover, the apoptosis rates of Hep3B (Figure 3E, \( P < 0.001 \)) and SK-Hep1 cells (Figure 3F, \( P < 0.001 \)) were slightly increased under hypoxia. HIF-1α silencing significantly increased the apoptosis rates of Hep3B (Figure 3E, \( P < 0.001 \)) and SK-Hep1 cells (Figure 3F, \( P < 0.001 \)) under hypoxia, which was partially reversed by NEAT1 overexpression (Figure 3E and 3F, \( P < 0.001 \)).

As shown in Figure 4A-E, NEAT1 overexpression further promoted migration and invasion under hypoxia (\( P < 0.001 \)), while HIF-1α silencing noticeably suppressed migration and invasion under hypoxia (\( P < 0.001 \)), and the effects of HIF-1α silencing were partially reversed by NEAT1 overexpression (\( P < 0.001 \)).

**Knocking down HIF-1α inhibited tumor growth in vivo through negatively regulating NEAT1 expression**

To evaluate the effects of siHIF-1α and NEAT1 on the tumor growth of HCC cells in vivo, we established a xenograft model in which the Hep3B cells treated with siHIF-1α, or pc-NEAT1, or siHIF-1α and pc-NEAT1 were subcutaneously injected into the flank of athymic mice, respectively. The xenograft model was allowed to develop measurable tumors. The volume (Figure 5A and 5C, \( P < 0.001 \)) and weight (Figure 5A and 5D, \( P < 0.001 \)) of the tumors in the siHIF-1α group were significantly smaller and lighter than those in the control group, which, however, were reversed by pc-NEAT1 (Figure 5A, 5C and 5D, \( P < 0.001 \)).

Next, qRT-PCR analysis of NEAT1 expression and immunostaining analysis of HIF-1α protein expression were performed in resected tumor tissues. As described in Figure 5E, the relative level of NEAT1 expression in the siHIF-1α group was significantly lower than that in the control group (\( P < 0.001 \)), which was reversed by pc-NEAT1 (\( P < 0.001 \)). As described in Figure 5B, siHIF-1α reduced the protein level of HIF-1α, while pc-NEAT1 did not affect the protein level of HIF-1α.

Collectively, our in vivo and in vitro data supported that NEAT1 can act as an oncogenic lncRNA in HCC, and its expression can be suppressed by HIF-1α knockdown.

**Discussion**

In the study, the data showed that NEAT1 and HIF-1α were highly expressed in HCC. Consistent with our findings, a recent study revealed that NEAT1 was obviously up-regulated in HCC tissues and cells [20]. We also found that higher expressions of HIF1α and NEAT1 were associated with poorer prognosis in HCC patients. Moreover, studies showed that in human HCC tissues, HIF1α is highly elevated and is associated with poorer prognosis [21, 22]. Li G et al. reported that IncRNA plays an important role in tumorigenesis, subsequent prognosis and metastasis of HCC [23], which is consistent with our findings that higher NEAT1 expression was closely associated with advanced TNM stage, metastasis and prognosis in HCC patients. Liu Z et al. suggested that in HCC tissues...
The role of HIF-1α and NEAT1 in hepatocellular carcinoma

A

![Graphs showing relative NEAT1 expression levels for Hep3B and SK-Hep1 cells under different conditions.](image)

B

![Graphs showing relative NEAT1 expression levels for Hep3B and SK-Hep1 cells under different conditions.](image)

C

![Graphs showing relative cell viability rates for Hep3B and SK-Hep1 cells under different conditions.](image)

D

![Graphs showing relative cell viability rates for Hep3B and SK-Hep1 cells under different conditions.](image)

E

![Flow cytometry images for Hep3B and SK-Hep1 cells under different conditions.](image)

F

![Flow cytometry images for Hep3B and SK-Hep1 cells under different conditions.](image)
NEAT1 overexpression is an independent risk factor associated with the prognosis of HCC patients [24]. Besides, our data directly confirmed that HIF-1α expression was positively correlated with NEAT1 expression in HCC tissues. Taken together, expressions of HIF-1α and NEAT1 have high predictive and diagnostic values and can serve as prognostic markers and treatment targets for HCC.

Hypoxia is a general symptom in solid cancers and is particularly common in HCC due to its rapid growth [25]. Hypoxia is closely related to tumor progression and negatively affects overall prognosis [26]. Our results demonstrated that HIF-1α and NEAT1 were highly expressed in HCC cells under hypoxia, suggesting that hypoxia caused poor prognosis to HCC patients possibly through overexpressing HIF-1α and NEAT1. Moreover, Co-IP results demonstrated that HIF-1α promoted NEAT1 transcription directly binding to the HRE in the promoter region of NEAT1, which were consistent with the correlation of HIF-1α and NEAT1 in HCC tissues and the result that NEAT1 expression was inhibited by down-regulating the expression of HIF-1α. In view of this, we suggested that the overexpression of NEAT1 was induced partly by HIF-1α directly binding to the NEAT1 promoter in HCC cells under hypoxia. Therefore, we elucidated that it might be a promising therapeutic option of HCC to inhibit the expression of NEAT1 by HIF-1α silencing.

In the present study, the results demonstrated that NEAT1 further promoted the HCC cell development, evidenced by increased cell viability, migration and invasion, and suppressed apoptosis in HCC cells under hypoxia, while HIF-1α silencing further promoted the above phenomena. Consistently, previous study showed that down-regulating the expression of NEAT1 not only suppressed proliferation, migration, and invasion of HCC cells, but also promoted apoptosis of HCC cells [27]. We also found that the effects of NEAT1 overexpression in HCC cells under hypoxia were partially reversed by HIF-1α silencing. Migration refers to any directed cell movement within the body, and invasion of carcinomas is the penetration of tissue barriers [28]. The migration and invasion abilities of cancer cells enables diseases to spread through changing position within tissues or from the initial tumor [29]. Cancer cell migration and invasion into surrounding tissues and vasculature are the pivotal and initial events in cancer metastasis [29]. Frequent tumor metastasis will bring dismal outcome to HCC patients [30]. Thus, inhibition of HIF-1α might suppress HCC development and improve prognosis by negatively regulating the expression of NEAT1 under hypoxia. In addition, the results from xenograft tumor assays in nude mice further revealed that HIF-1α silencing suppressed HCC malignant progression in vitro through inhibiting the expression of NEAT1.

In brief, our results provide novel findings that improve the current understanding on HCC pathogenesis and provide a promising strategy for the diagnosis and treatment of HCC. However, HCC progression is a complex process involving the most gene networks and changes in signaling pathways, many of which still need to be illuminated [31]. For example, Ling Z A et al. [27] reported that NEAT1 promotes the development of HCC through interacting with several tumor-related genes such as SP1 and KAT2A; Mang Y et al. [32] found that NEAT1 promotes cell proliferation and invasion through modulating hnRNP A2 expression in HCC cells. These findings suggested that the mechanism of HIF-1α and NEAT1 in HCC under hypoxia may involve other downstream targets, yet more experiments are needed to fully elucidate the role of NEAT1 in HCC development.
The role of HIF-1α and NEAT1 in hepatocellular carcinoma
required to be performed in appropriate cells or animal models to confirm this hypothesis. However, the generate more data of some mechanistic studies should be further explore for supporting the observation and conclusion in this study.

Conclusion

Taken together, the study demonstrates that NEAT1 acts as an oncogene by promoting malignant development, and that higher expression of NEAT1 predicts a poorer prognosis.
of human HCC. The expression of NEAT1 could be suppressed by down-regulating the expression of HIF-1α.

Acknowledgements

This work was supported by the Young Talents Program of Jiangsu Cancer Hospital [Grant Number QL201801]; the National Natural Science Foundation of China [Grant Number 81872485]. Thanks for the financial supports.

Disclosure of conflict of interest

None.

Address correspondence to: Wenrong Shen, Department of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, No. 42, Baiziting, Xuanwu District, Nanjing 210000, Jiangsu, China. Tel: +86-025-83283502; E-mail: shenwr_wrong@163.com

References


